<DOC>
	<DOCNO>NCT02214121</DOCNO>
	<brief_summary>The purpose Phase II dose-ranging study investigate pharmacokinetic ( PK ) pharmacodynamic ( PD ) property various dos ticagrelor follow 4 week twice-daily treatment paediatric patient sickle cell disease</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) Dose-ranging Phase II Study Ticagrelor Paediatric Patients With Sickle Cell Disease</brief_title>
	<detailed_description>This multicenter , open-label , dose-ranging study ticagrelor follow double blind , placebo-controlled extension phase paediatric patient sickle cell disease ( SCD ) . Part A : Patients randomise 1:1 receive one two dosing schedule consist two single weight-adjusted dos ticagrelor . Pharmacokinetic ( PK ) parameter pharmacodynamic ( PD ) measurement determine follow dose . Platelet aggregation measure use VerifyNow™ P2Y12 assay . Following 2 single dos , patient receive open-label one-week treatment ticagrelor twice daily determine tolerability prior randomisation Part B . Part B : In part patient randomise ( 2:1 ratio ) ticagrelor twice daily placebo 4-week treatment phase . During study , patient follow occurrence vaso-occlusive crisis ( VOC ) disease manifestation daily pain , analgesic use complication SCD .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Inclusion criterion Children age ≥2 &lt; 18 year age Diagnosed homozygous sickle cell ( HbSS ) sickle betazerothalassaemia ( HbS/β0 ) Exclusion criterion At risk haemorrhagic bradycardic event Significant hepatic impairment Renal failure require dialysis Concomitant oral intravenous therapy strong CYP3A4 ( cytochrome ) inhibitor , CYP3A4 substrates narrow therapeutic index , strong CYP3A4 inducer . Surgical procedure plan occur study . Patients currently pregnant breastfeed plan become pregnant study . Patients know hypersensitivity contraindication ticagrelor .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>sickle cell anemia</keyword>
	<keyword>paediatric</keyword>
</DOC>